Trastuzumab Deruxtecan in HER2-Low Breast Cancer

被引：0
|
作者：
Carroll, Hailey K. [1 ]
Higgins, Michaela J. [2 ]
O'Reilly, Seamus [1 ]
机构：
[1] Cork Univ Hosp, Cork, Ireland
[2] St Vincents Univ Hosp, Dublin, Ireland
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2022年 / 387卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1144 / 1144
页数：1
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study
    Modi, Shanu
    FUTURE ONCOLOGY, 2025, 21 (04) : 367 - 380
  • [32] Cost-effectiveness analysis of trastuzumab deruxtecan in patients with HER2-low advanced breast cancer based on DESTINY-Breast04
    Zhan, Mei
    Huang, Zijia
    Xu, Ting
    Xu, Xinyi
    Zheng, Hanrui
    Wu, Fengbo
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [33] Activity and tolerability of combination of trastuzumab deruxtecan with the pan-AKT inhibitor capivasertib in preclinical HER2+and HER2-low breast cancer models
    Bashi, Azadeh Cheraghchi
    Proia, Theresa
    Randle, Suzanne
    Anderton, Mark
    Rasheed, Zeshaan
    Pease, J. Elizabeth
    Barry, Simon
    Carroll, Danielle
    Mettetal, Jerome
    CANCER RESEARCH, 2022, 82 (04)
  • [34] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Trastuzumab Deruxtecan in patients with Unstable Central Nervous System Involvement from HER2-Low Advanced Breast Cancer: The DEBBRAH Trial
    Perez-Garcia, Jose Manuel
    Batista, Marta Vaz
    Cortez-Castedo, Patricia
    Borrego, Manuel Ruiz
    Cejalvo, Juan Miguel
    de la Haba-Rodriguez, Juan
    Garrigos, Laia
    Racca, Fabriccio
    Servitja, Sonia
    Blanch, Salvador
    Gion, Maria
    Nave, Monica
    Fernandez, Adela
    Martinez-Bueno, Alejandro
    Llombart-Cussac, Antonio
    Sampayo-Cordero, Miguel
    Malfettone, Andrea
    Cortes, Javier
    Braga, Sofia
    CANCER RESEARCH, 2023, 83 (05)
  • [36] Safety and efficacy of trastuzumab deruxtecan for metastatic HER2+and HER2-low breast cancer: An updated systematic review and meta-analysis of clinical trials
    Qureshi, Zaheer
    Altaf, Faryal
    Jamil, Abdur
    Siddique, Rimsha
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [37] Trastuzumab Deruxtecan in HER2-positive metastatic Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2024, 84 (08) : 670 - 670
  • [38] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study
    Jourdain, Hugo
    Desplas, David
    Mansouri, Imene
    Zureik, Mahmoud
    Di Meglio, Antonio
    Haddy, Nadia
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 531 - 531
  • [39] Cost-Effectiveness of Trastuzumab Deruxtecan in Patients with Unresectable or Metastatic HER2-Low Breast Cancer Who Have Received Prior Chemotherapy
    Paulissen, Jeroen Hendrikus Jacobus
    van Schoonhoven, Alexander Victor
    Olin, Emma
    Postma, Arjan Jacobus
    Mbanya, Zacharie
    Dunton, Kyle John
    Postma, Maarten Jacobus
    van Hulst, Marinus
    Freriks, Roel Donald
    ADVANCES IN THERAPY, 2025, 42 (01) : 322 - 333
  • [40] Trastuzumab deruxtecan versus chemotherapy for patients with HER2-low advanced breast cancer: A US-based cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Zhu, Xiaolu
    Qin, Qun
    Zhu, Hong
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345